Onconetix, Inc. (ONCO) AI Stock Analysis
ONCO AI stock analysis summary
AI ResearchOnconetix, Inc. (ONCO) is a biotechnology firm focused on oncology and men's health therapeutics and diagnostics, with a market capitalization of $2.5M. The company recorded trailing twelve month revenue of $645,824 but continues to face substantial operational losses, with an operating margin of -13112.1%. Over the past year, the stock's return of -99.7% substantially lagged the S&P 500 (SPY) return of 16.8%.
- Market cap
- $2.5M
- Revenue (TTM)
- $645,824
- P/E
- 0.0x
- 1Y return
- -99.7% S&P 500 16.8%
- Avg. target
- $9.00 1778.9% vs last close
Bull case
- Onconetix maintains a net cash position of $5.8M with total debt of just $187,128 as of June 30, 2026.
- Gross margin improved over the fiscal periods, rising from -1927.9% in FY2023 to 77.6% in FY2025.
- Wall Street analysts set a mean price target of $9.00, representing an upside of 1778.9% over the last close price of $0.48.
Bear case
- Quarterly revenue fell 83.9% year-over-year in the period ended June 30, 2026, leading to TTM revenue of $645,824.
- The company remains deeply unprofitable with a trailing twelve month operating margin of -13112.1% and FY2025 net income of -$14.0M.
- Shareholder dilution has been substantial, evidenced by a 19573.7% change in share count over five years.
What Onconetix does
Headquartered in Cincinnati, Ohio, Onconetix, Inc. is a biotechnology company focused on advancing solutions in men's health and oncology through research, development, and commercialization. Formerly known as Blue Water Biotech, Inc., the company changed its name in December 2023. Its key offerings include Entadfi, an FDA-approved once-daily pill combining finasteride and tadalafil for the treatment of benign prostatic hyperplasia (BPH). Additionally, Onconetix has developed Proclarix, an in vitro protein-based blood diagnostic test tailored for the early detection of prostate cancer to support personalized treatment approaches.
Growth and profitability
Onconetix generated revenue of $58,465 in FY2023, which expanded to $2.5M in FY2024 before decreasing 67.7% to $815,371 in FY2025. Gross margin improved from -1927.9% in FY2023 to 41.8% in FY2024 and 77.6% in FY2025. However, operating losses remained elevated, with an operating margin of -778.2% and net income of -$14.0M in FY2025, corresponding to an EPS of -$55.87. Research and development expenses declined from $1.9M in FY2023 to $66,133 in FY2025. In the latest quarter ended June 30, 2026, quarterly revenue dropped 83.9% year-over-year, contributing to trailing twelve month revenue of $645,824 and an operating margin of -13112.1%.
Balance sheet and cash flow
As of June 30, 2026, Onconetix held $5.9M in cash and short-term investments and $187,128 in total debt, resulting in a net cash position of $5.8M. Total assets stood at $16.4M against shareholders' equity of $13.5M, with a current ratio of 2.21 and a debt-to-equity ratio of 0.01. Operating cash flow was -$9.7M in FY2025, matching free cash flow of -$9.7M. During FY2025, cash deployment included $1.7M spent on share buybacks, while the five-year share count change was 19573.7%.
Valuation and performance
At a last close price of $0.48, Onconetix trades at a price-to-sales multiple of 3.9x, compared to 4.1x for the median of its US-listed Healthcare peers. Its enterprise value stands at -$2.8M, reflecting an EV to revenue multiple of 0.2x. The stock trades at a price-to-book ratio of 0.2x and a trailing P/E of 0.0x, compared to a peer median trailing P/E of 24.6x. Over the past year, ONCO fell 99.7%, trailing the S&P 500 (SPY) gain of 16.8%, and trades 97.3% below its 200-day average.
What analysts expect
Wall Street analysts maintain a mean price target of $9.00 for ONCO, which is 1778.9% above the last close price of $0.48. Over the last four quarters, the company recorded 0 EPS beats. The company's next earnings date is scheduled for November 12, 2026.
Key risks and what to watch
- Continued negative operating cash flow, which stood at -$9.7M in FY2025, threatens liquidity despite $5.9M in cash.
- The stock displays extreme volatility with a beta of 2.61 and a 1-year decline of 99.7%.
- Short interest represents 9.3% of the float, reflecting market skepticism.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this ONCO AI stock analysis
This page is an AI-written research summary of Onconetix, Inc. (ONCO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: ONCO income statement, ONCO balance sheet, ONCO key metrics, ONCO chart. See the ONCO stock overview for the latest quote and news.
ONCO AI stock analysis FAQ
What products does Onconetix develop?
Onconetix focuses on men's health and oncology, primarily offering Entadfi, an FDA-approved daily pill for benign prostatic hyperplasia, and Proclarix, a blood-based diagnostic test for detecting prostate cancer.
What is Onconetix's cash and debt position?
As of June 30, 2026, Onconetix had $5.9M in cash and short-term investments and $187,128 in total debt, leaving it with $5.8M in net cash.
How has ONCO stock performed recently?
As of October 16, 2026, ONCO closed at $0.48, down 99.4% year-to-date and 99.7% over the trailing one-year period, while trading 97.3% below its 200-day average.
When is Onconetix's next earnings report?
Onconetix is scheduled to report its next earnings on November 12, 2026.